The Outcome of the Chemotherapy and Oncothermia for Far Advanced Adenocarcinoma of the Lung: Case Reports of Four Patients


Lung cancer is one of the most aggressive and lethal form of cancers. Patients with far advanced lung cancer are treated by chemotherapy with or without radiotherapy. However, median survival of these patients is less than 6 months. To increase survival and quality of life for these patients, various forms of complementary treatments have been tried in clinical practices, and oncothermia is supposed to be one of the promising candidates. From May 2008 to November 2013, 4 patients with far advanced lung adenocarcinoma (stages IIIB and IV) were treated with oncothermia in addition to conventional chemotherapy at Gangnam Severance Hospital and Bundang CHA Hospital. All these patients have survived for more than 2 years.

Share and Cite:

Lee, D. , Park, J. , Jung, H. , Byun, E. , Haam, S. and Lee, S. (2015) The Outcome of the Chemotherapy and Oncothermia for Far Advanced Adenocarcinoma of the Lung: Case Reports of Four Patients. Advances in Lung Cancer, 4, 1-7. doi: 10.4236/alc.2015.41001.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Owonikoko, T.K., Ragin, C.C., Belani, C.P., Oton, A.B., Gooding, W.E., Taioli, E. and Ramalingam, S.S. (2007) Lung Cancer in Elderly Patients: An Analysis of the Surveillance, Epidemiology, and End Results Database. Journal of Clinical Oncology, 25, 5570-5577.
[2] Siegel, R. (2013) Cancer Statistics. Ca—Cancer Journal for Clinicians, 63, 11-30.
[3] Polo, V. and Besse, B. (2014) Maintenance Strategies in Stage IV Non-Small-Cell Lung Cancer (NSCLC): In Which Patients, With Which Drugs? Annals of Oncology 25, 1283-1293.
[4] Akcali, Z., Calikusu, Z., Sakalli, H. and Ozyilkan, O. (2008) Gemcitabine and Cisplatin Treatment of Advanced-Stage Non-Small-Cell Lung Cancer in Patients Given Cisplatin on Day 8. Tumori, 94, 474-480.
[5] Kawano, Y., Ohyanagi, F., Yanagitani, N., Kudo, K., Horiike, A., Tanimoto, A., Nishizawa, H., Ichikawa, A., Sakatani, T., Nakatomi, K., Hagiwara, S., Ninomiya, H., Motoi, N., Ishikawa, Y., Horai, T. and Nishio, M. (2013) Pemetrexed and Cisplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer in Japanese Patients: Phase II Study. Anticancer Research, 33, 3327-3333.
[6] Szasz, A. (2014) Current Status of Oncothermia Therapy for Lung Cancer, The Korean Journal of Thoracic and Cardiovascular Surgery, 47, 77-93.
[7] Szasz, A., Szasz, N. and Szasz, O. (2010) Oncothermia—Principles and Practices. Springer, Dordrecht.
[8] Szasz, A. (2013) Challenges and Solutions in Oncological Hyperthermia, Thermal Medicine, 29, 1-23.
[9] Szasz, A., Szasz, N. and Szasz, O. (2013) Local Hyperthermia in Oncology. In: Huilgol, N., Ed., Hyperthermia, InTech, Winchester, 1-82.
[10] Szasz, A. (2013) Electromagnetic Effects in Nanoscale Range. In: Shimizu, T. and Kondo, T., Eds., Cellular Response to Physical Stress and Therapeutic Application, Nova Science Publishers, Inc., New York, 55-81.
[11] Szasz, A., Vincze, Gy., Szasz, O. and Szasz, N. (2003) An Energy Analysis of Extracellular Hyperthermia. Electromagnetic Biology and Medicine, 22, 103-105.
[12] Szasz, O. and Szasz, A. (2014) Oncothermia—Nano-Heating Paradigm. Journal of Cancer Science and Therapy, 6, 117-121.
[13] Meggyeshazi, N., Andocs, G., Balogh, L., Balla, P., Kiszner, G., Teleki, I., Jeney, A. and Krenacs, T. (2014) DNA Fragmentation and Caspase-Independent Programmed Cell Death by Modulated Electrohyperthermia. Strahlentherapie und Onkologie, 190, 815-822.
[14] Andocs, G., Meggyeshazi, N., Balogh, L., Spisak, S., Maros M.E., Balla, P., Kiszner, G., Teleki, I., Kovago, Cs. and Krenacs, T. (2014) Upregulation of Heat Shock Proteins and the Promotion of Damage-Associated Molecular Pattern Signals in a Colorectal Cancer Model by Modulated Electrohyperthermia. Cell Stress and Chaperones, 20, 37-46.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.